A quick simple method of determining platelet aggregability following glycoprotein IIb/IIIa receptor inhibitor administration.
Platelet aggregation assessment after therapeutic administration of a GP IIb/IIIa inhibitor has been difficult in routine practice due to the inherent nature of platelet preparation and aggregometry. Platelet microaggregation was performed via the utilisation of a Coulter counter. Citrate and heparin were evaluated as the anticoagulants, and ADP and adrenaline were evaluated as the stimulants. Aprotinin was also assessed. ReoPro was utilised in all assays as the GP IIb/IIIa inhibitor. Platelet microaggregation using the described methodology provides a quick, simple, reliable, and clinically valid method of assessing the percentage platelet inhibition due to the presence of a GP IIb/IIIa inhibitor.
Poullis
M
M
Department of Cardiothoracic Surgery, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, London, UK. mpoullis@rpms.ac.uk
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D007611:Aprotinin / Q000494:pharmacology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D010979:Platelet Function Tests / Q000379:methods*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D007611:Aprotinin; D000077284:Abciximab